Advancing new research

The Interlaken Leadership Awards

Interlaken Leadership Awards Recipients

Past Recipients

2018 Emilie Mathey (Australia)

The effectiveness of IVIg in anti-NF155 IgG mediated CIDP
2017 Maarten Titulaer (Netherlands)

IVIg treatment for autoimmune epilepsy with neuronal antibodies
- Jean-Christophe Camdessanché (France)
  
  Identification, validation, and characterization of novel autoantigens in the serum of patients with CIDP
2016 Anneke van der Kooi (Netherlands)

Early intravenous immunoglobulin (IVIg) treatment in newly diagnosed idiopathic inflammatory myopathies (myositis): a proof of principle study.
- Lisa Christopher-Stine (USA)
  
  Low dose intravenous and subcutaneous IG for the maintenance treatment of statin-induced anti-HMGCR-associated myopathy: A prospective pilot study.
2015 Mohammad Alsharabati (USA)

Subcutaneous vs. intravenous IgG in treatment of neuromuscular junction disorders
2014 Bart Jacobs (Netherlands)

Immunoglobulin treatment for patients with mild Guillain-Barré syndrome: an international prospective observational study.
2013 Andrew J Pollard (UK)

Intravenous immunoglobulin in the management of encephalitis in children.
- Min-Suk Yoon (Germany)
  
  Effects of intrathecal application of human immunoglobulins (Igs) on rat EAN Model.
- Peter Novak (USA)
  
  Treatment of multiple system atrophy (MSA) using intravenous immunoglobulins (IVIG)
2012 Josep Gamez (Spain)

Intravenous immunoglobulin for preparing masthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis.
- Cory Toth (Canada)
  
  A cross-over study of SCIG therapy for early onset of diabetic peripheral neuropathic pain.
- Milan Basta (US)
  
  IVIG in acute ischemic stroke.
- Cindy Shin-Yi Lin, (Australia)
  
  Nerve excitability substudy of polyneuropathy and subcutaneous immunoglobulin treatment in patients with CIDP
2011 Jean-Yves Delattre (France)

IaSON: Privigen in paraneoplastic syndrome
- Christian Geis (Germany)
  
  Treatment effects of polyvalent human immunoglobulins in an animal model of neuromyelitis optica.
- Andreas Goebel (UK)
  
  Cellular and behavioural models to predict patients' responses to IgG treatment in CRPS.
- Ruth Itzhaki (UK)
  
  Does Privigen affect the accumulation of Aβ and P-tau that occurs in HSV1-infected cultures of Vero cells.
- Jens Schmidt (Germany)
  
  Immunoglobulin G for experimental treatment of Duchenne muscular dystrophy
- Nancy Nealon (US)
  
  Prevention of relapses in neuromyelitis spectrum patients with IVIG